✦ LIBER ✦

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

✍ Scribed by Hueber, W.; Sands, B. E.; Lewitzky, S.; Vandemeulebroecke, M.; Reinisch, W.; Higgins, P. D. R.; Wehkamp, J.; Feagan, B. G.; Yao, M. D.; Karczewski, M.; Karczewski, J.; Pezous, N.; Bek, S.; Bruin, G.; Mellgard, B.; Berger, C.; Londei, M.; Bertolino, A. P.; Tougas, G.; Travis, S. P. L.

Book ID: 115538148
Publisher: BMJ Publishing Group
Year: 2012
Tongue: English
Weight: 304 KB
Volume: 61
Category: Article
ISSN: 0017-5749
DOI: 10.1136/gutjnl-2011-301668

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Secukinumab, a human anti-IL-17A monoclo

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blindplacebo- controlled trial

✍ Hueber, Wolfgang (author);Sands, Bruce E. (author);Lewitzky, Steve (author);Vand 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 304 KB

Secukinumab, a human anti-IL-17A monoclo

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blindplacebo- controlled trial

✍ Hueber, Wolfgang (author);Sands, Bruce E. (author);Lewitzky, Steve (author);Vand 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 304 KB

Mepolizumab, a Humanized Monoclonal Anti

Mepolizumab, a Humanized Monoclonal Antibody to IL-5, for Severe Eosinophilic Esophagitis in Adults: A Randomized, Placebo-Controlled Double-Blind Trial

✍ STRAUMANN, A; CONUS, S; KITA, H; KEPHART, G; BUSSMANN, C; BEGLINGER, C; PATEL, J 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

Efficacy and safety results of secukinum

Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease

✍ B. G. Feagan; W. J. Sandborn; J. P. Baker; F. Cominelli; L. R. Sutherland; C. O 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB